## Abdurrahman Mithat Bozdayi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3729128/publications.pdf

Version: 2024-02-01

71 papers

1,861 citations

257101 24 h-index 276539 41 g-index

71 all docs

71 docs citations

71 times ranked

2271 citing authors

#	Article	IF	CITATIONS
1	Cytotoxic CD4+ T cells in viral hepatitis. Journal of Viral Hepatitis, 2006, 13, 505-514.	1.0	130
2	Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV†study. Hepatology, 2018, 67, 1224-1236.	3.6	117
3	Treatment of chronic delta hepatitis with lamivudine <i>vs</i> lamivudineâ€f+â€finterferon <i>vs</i> interferon. Journal of Viral Hepatitis, 2008, 15, 314-321.	1.0	115
4	Famciclovir treatment of chronic delta hepatitis. Journal of Hepatology, 2002, 37, 266-271.	1.8	103
5	Molecular epidemiology of hepatitis B, C and D viruses in Turkish patients. Archives of Virology, 2004, 149, 2115-2129.	0.9	93
6	Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. Journal of Viral Hepatitis, 2004, 11, 141-147.	1.0	80
7	Thrombophilic gene mutations in cirrhotic patients with portal vein thrombosis. European Journal of Gastroenterology and Hepatology, 2005, 17, 339-343.	0.8	62
8	Complete genome sequence and phylogenetic analysis of hepatitis B virus isolated from turkish patients with chronic HBV infection. Journal of Medical Virology, 2005, 76, 476-481.	2.5	61
9	A pilot study of 2 years of interferon treatment in patients with chronic delta hepatitis. Journal of Viral Hepatitis, 2007, 14, 812-816.	1.0	61
10	<scp>HB</scp> eAgâ€positive hepatitis delta: virological patterns and clinical longâ€term outcome. Liver International, 2012, 32, 1415-1425.	1.9	52
11	YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine. Journal of Viral Hepatitis, 2003, 10, 256-265.	1.0	50
12	Entecavir Treatment of Chronic Hepatitis D. Clinical Infectious Diseases, 2012, 55, 645-650.	2.9	50
13	NOD2/CARD15, NOD1/CARD4, and ICAM-1 gene polymorphisms in Turkish patients with inflammatory bowel disease. Journal of Gastroenterology, 2006, 41, 304-310.	2.3	49
14	Effect of Turkish propolis extracts on proteome of prostate cancer cell line. Proteome Science, 2011, 9, 74.	0.7	46
15	Serum cytotoxin and oxidant stress markers in N-acetylcysteine treated thioacetamide hepatotoxicity of rats. Human and Experimental Toxicology, 1999, 18, 669-676.	1.1	38
16	A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis—end of treatment results from the LOWR HDV-2 study. Journal of Hepatology, 2017, 66, S33-S34.	1.8	38
17	Screening for hemochromatosis in Turkey. Journal of Hepatology, 2002, 36, 254-255.	1.8	34
18	Bronchoalveolar lavage fluid analysis in individuals with chronic hepatitis C. Journal of Medical Virology, 2002, 66, 34-39.	2.5	34

#	Article	IF	CITATIONS
19	Lamivudine vs lamivudine and interferon combination treatment of HBeAg(-) chronic hepatitis B. Journal of Viral Hepatitis, 2005, 12, 262-268.	1.0	34
20	Nucleotide divergences in the core promoter and precore region of genotype D hepatitis B virus in patients with persistently elevated or normal ALT levels. Journal of Clinical Virology, 2001, 21, 91-101.	1.6	31
21	Pegylated interferon-alpha plus taurine in treatment of rat liver fibrosis. World Journal of Gastroenterology, 2007, 13, 3237.	1.4	30
22	Hepatitis B surface antigen seroconversion is associated with favourable longâ€term clinical outcomes during lamivudine treatment in HBeAgâ€negative chronic hepatitis B patients. Journal of Viral Hepatitis, 2012, 19, 220-226.	1.0	28
23	Antimicrobial and Antiviral Screening of Novel Indole Carboxamide and Propanamide Derivatives. Zeitschrift Fur Naturforschung - Section C Journal of Biosciences, 2008, 63, 189-195.	0.6	25
24	Fatigue of cholestasis and the serotoninergic neurotransmitter system in the rat. Hepatology, 2005, 41, 731-737.	3.6	24
25	The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country. European Journal of Health Economics, 2012, 13, 663-676.	1.4	24
26	Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis. Turkish Journal of Gastroenterology, 2012, 23, 560-568.	0.4	22
27	Polymorphism of Precore Region of Hepatitis B Virus DNA among Patients with Chronic HBV Infection in Turkey. Infection, 1999, 27, 357-360.	2.3	21
28	Prevalence of hepatitis-G virus and hepatitis-C virus infection in patients with non-Hodgkin's lymphoma. Medical Oncology, 2000, 17, 123-126.	1.2	20
29	Interleukinâ€28 gene polymorphisms may contribute to <scp>HB</scp> sAg persistence and the development of <scp>HB</scp> eAgâ€negative chronic hepatitis B. Liver International, 2015, 35, 846-853.	1.9	20
30	A short course of addâ€on adefovir dipivoxil treatment in lamivudineâ€resistant chronic hepatitis B patients. Journal of Viral Hepatitis, 2009, 16, 279-285.	1.0	19
31	A one step real time PCR method for the quantification of hepatitis delta virus RNA using an external armored RNA standard and intrinsic internal control. Journal of Clinical Virology, 2014, 60, 11-15.	1.6	19
32	Complete genome sequences and phylogenetic analysis of hepatitis delta viruses isolated from nine Turkish patients. Archives of Virology, 2011, 156, 2215-2220.	0.9	18
33	Serum connective tissue markers as predictors of advanced fibrosis in patients with chronic hepatitis B and D. Turkish Journal of Gastroenterology, 2011, 22, 305-314.	0.4	18
34	Tumour necrosis factorâ€alpha, interleukinâ€10, interferonâ€gamma and vitamin <scp>D</scp> receptor gene polymorphisms in patients with chronic hepatitis delta. Journal of Viral Hepatitis, 2014, 21, 297-304.	1.0	17
35	Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection. Journal of Clinical Virology, 2012, 53, 130-134.	1.6	16
36	Hepatitis C virus genotype distribution in Turkey remains unchanged after a decade: Performance of phylogenetic analysis of the NS5B, E1, and 5'UTR regions in genotyping efficiency. Turkish Journal of Gastroenterology, 2014, 25, 405-410.	0.4	16

#	Article	IF	CITATIONS
37	Effects of Heparin Coating of Cardiopulmonary Bypass Circuits on In Vitro Oxygen Free Radical Production During Coronary Bypass Surgery. Artificial Organs, 1996, 20, 1008-1016.	1.0	15
38	Influence of Two Blood Conservation Techniques (Cardiotomy Reservoir Versus Cell-Saver) on Biocompatibility of the Heparin Coated Cardiopulmonary Bypass Circuit During Coronary Revascularization Surgery. Journal of Cardiac Surgery, 1997, 12, 190-197.	0.3	14
39	Circulating IL-2 and IL-10 in Chronic Active Hepatitis C with Respect to the Response to IFN Treatment. Infection, 2000, 28, 309-313.	2.3	14
40	Remission of severe aplastic anemia associated with hepatitis B virus infection after viral clearance: potential role of lamivudine. Digestive Diseases and Sciences, 2002, 47, 1782-1785.	1.1	14
41	Screening for Hemochromatosis in Turkey. Digestive Diseases and Sciences, 2004, 49, 444-449.	1.1	13
42	Cutaneous, pulmonary and hepatic sarcoidosis associated with autoimmune complications during interferon-alpha treatment for hepatitis C virus infection. Journal of the European Academy of Dermatology and Venereology, 2006, 20, 442-445.	1.3	13
43	Importance of Serum SELDI-TOF-MS Analysis in the Diagnosis of Early Lung Cancer. Asian Pacific Journal of Cancer Prevention, 2013, 14, 2037-2042.	0.5	13
44	Effects of Prostacyclin on Heparin Reversal with Protamine. Vascular Surgery, 1992, 26, 464-473.	0.3	12
45	Screening for Iron Overload in the Turkish Population. Digestive Diseases, 2003, 21, 279-285.	0.8	12
46	Clonal Analysis of the Quasispecies of Antiviral-Resistant HBV Genomes in Patients with Entecavir Resistance during Rescue Treatment and Successful Treatment of Entecavir Resistance with Tenofovir. Antiviral Therapy, 2013, 18, 77-85.	0.6	12
47	Emergence of a Novel Mutation in the FLLA Region of Hepatitis B Virus during Lamivudine Therapy. Antimicrobial Agents and Chemotherapy, 2005, 49, 2618-2624.	1.4	11
48	Inhibition of hepatitis B virus replication by shRNAs in stably HBV expressed HEPG2 2.2.15 cell lines. Archives of Virology, 2007, 152, 871-879.	0.9	11
49	Efficacy of tenofovir in adefovir-experienced patients compared to treatment-naive patients with chronic hepatitis B. Antiviral Therapy, 2014, 19, 543-550.	0.6	11
50	Investigation of West Nile virus among healthy blood donors in the western part of Turkey. Turkish Journal of Medical Sciences, 2015, 45, 84-88.	0.4	10
51	Free circulating nucleic acids in plasma and serum as a novel approach to the use of internal controls in real time PCR based detection. Journal of Virological Methods, 2014, 207, 133-137.	1.0	9
52	The beneficial effects of aminophylline administration on heparin reversal with protamine. Surgery Today, 1994, 24, 99-102.	0.7	8
53	Oral Ganciclovir for Treatment of Lamivudineâ€Resistant Hepatitis B Virus Infection: A Pilot Study. Clinical Infectious Diseases, 2002, 35, 960-965.	2.9	8
54	Interferon-alpha2b induction treatment with or without ribavirin in chronic hepatitis C: a multicenter, randomized, controlled trial. Digestive Diseases and Sciences, 2003, 48, 1124-1129.	1.1	7

#	Article	IF	CITATIONS
55	The role of HBeAg seroconversion in acute exacerbation of liver disease with termination of hepatitis B and D virus infection in a chronic hepatitis D patient during $\hat{l}_{\pm}$ -interferon therapy. European Journal of Gastroenterology and Hepatology, 2003, 15, 819-823.	0.8	7
56	A novel pattern (sW195a) in surface gene of HBV DNA due to YSDD (L180M plus M204S) mutation selected during lamivudine therapy and successful treatment with adefovir dipivoxil. Journal of Clinical Virology, 2004, 31, 76-77.	1.6	7
57	Role of immunohistochemistry for hepatitis D and hepatitis B virus in hepatitis delta. Liver International, 2014, 34, 1207-1215.	1.9	7
58	Discontinuation of Lamivudine Treatment in HBeAg-Negative Chronic Hepatitis B: A Pilot Study with Long-Term follow-up. Antiviral Therapy, 2017, 22, 559-570.	0.6	7
59	Influence of Viral Load and Alanine Aminotransferase on Viral Genetic Heterogeneity in Patients with Chronic Hepatitis C Virus Infection. Intervirology, 2000, 43, 61-66.	1.2	4
60	Potential proteomic biomarkers in assessing liver fibrosis using SELDI-TOF MS. Turkish Journal of Gastroenterology, 2012, 23, 46-53.	0.4	4
61	Trefoil Factor Expression in Biliary Epithelium of Graft-versus-Host Disease of the Liver after Allogeneic Hematopoietic Cell Transplantation. Transplantation, 2005, 80, 1099-1104.	0.5	3
62	Beneficial Effects of Prostacyclin on Pulmonary Function During Heparin Reversal with Protamine. Vascular Surgery, 1993, 27, 264-267.	0.3	0
63	Arachidonic acid metabolites as biocompatibility parameters for cellulosic membranes. Nephrology Dialysis Transplantation, 1999, 14, 1804-1805.	0.4	0
64	Lamivudine is not effective in the treatment of non-cirrhotic HBeAg (â^') chronic hepatitis B patients with low level viremia. Journal of Hepatology, 2002, 36, 100.	1.8	0
65	Predictive value of ALT and HBV DNA levels in response to sequential combination treatment of lamivudine and interferon in HBeAg—/ANTI-Hbe+ chronic hepatitis B. Journal of Hepatology, 2002, 36, 104.	1.8	0
66	Ganciclovir treatment of lamivudine-resistant HBV infection. Journal of Hepatology, 2002, 36, 229-230.	1.8	0
67	Long term follow up chronic hepatitis B patients treated with interferon. Journal of Hepatology, 2002, 36, 241.	1.8	O
68	The role of HBeAg seroconversion in acute exacerbation of liver disease with termination of hepatitis B and D virus infection in a chronic hepatitis D patient during ??-interferon therapy. European Journal of Gastroenterology and Hepatology, 2003, 15, 819-823.	0.8	0
69	Isolation of biliary lipid carrying vesicles, analysis of their biochemical properties and hepatic ABCG5 mRNA expression in diosgenin-fed rats. Turkish Journal of Biochemistry, 2012, 37, 167-174.	0.3	0
70	Late Failure of Combined Recombinant Hepatitis B Vaccine and Lamivudine in Treatment of a Patient with Chronic Hepatitis B. Southern Medical Journal, 2004, 97, 407-409.	0.3	0
71	Evaluation of Relationship Between Serum Protein Profiles and Lung Cancer by SELDI-TOF-MS (Surface) Tj ETQq1 Journal of Medical Sciences, 2012, 32, 1084-1089.	1 0.78431 0.1	.4 rgBT /Ove O